Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas

Table 3 Future directions - drugs that are currently studied in relapsed/refractory aggressive and indolent B cell lymphomas that can potentially be studied in the post autologous hematopoietic cell transplantation setting

Drug	Mechanism of action	Ongoing trials in relapsed/refractory aggressive and indolent B cell lymphomas (not in post auto-HCT setting)
CD-19 antibodies (MEDI-551)	IgG1k antibody-dependent cellular cytotoxicity enhanced anti-CD19 mAb	Phase I (NCT00983619)
		Phase II (with ICE/DHAP NCT01453205)
		Phase II (with PD-1 inhibitor NCT02271945)
MPDL3280A	Targets PD-L1 expressed on tumor cells and tumor-infiltrating immune cells	Phase I (with Obinutuzumab NCT02220842)
Polatuzumab vedotin	Antibody-drug conjugate that targets CD 79b on the B cell receptor complex	Phase II (with Rituximab or Obinutuzumab and Bendamustine NCT02257567)
Obinutuzumab (GA101)	Fully humanized IgG1 mAb that selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells	Phase Ib/II (with lenalidomide NCT01582776) Phase Ib/II (with lenalidomide NCT01995669)
Veltuzumab	A fully humanized mAb directed against the CD20 antigen.	Phase I/II (NCT01147393)
ABT-199	Oral selective small molecule inhibitor of the anti-apoptotic protein Bcl-2	Phase I (NCT02055820)
		Phase I (with BR NCT01594229)
		Phase II (with BR vs BR alone NCT02187861)
Alisertib	Oral selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase	Phase  I (with Romidepsin NCT01897012)
		Phase I (with Vorinostat NCT01567709)
		Phase I (with Bortezomib and Rituximab NCT01695941) Phase II (with +/- Rituximab NCT01812005)
SAR245409	Oral small molecule targeting the PI3K and mTOR kinases.	Phase I/II (NCT01587040)
Belinostat	HDAC inhibitor	Phase I (with Carfilzomib NCT02142530)
		Phase II (with Ibritumomab Tiuxetan NCT01686165)

ICE: Ifosfamide, carboplatin and etoposide; DHAP: Dexamethasone, high dose cytarabine, cisplatin; PD-1: Programmed death-1; BR: Bendamustine, rituximab; mAb: Monoclonal antibody; PI3K: Phosphatidylinositol 3 kinase; mTOR: Mammalian target of rapamycin.